Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
Arnon P. Kater(Amsterdam University Medical Centers), Mark‐David Levin(Albert Schweitzer Hospital), Jeanette K. Doorduijn(Erasmus MC Cancer Institute), Martine E.D. Chamuleau(Hovon), Michel van Gelder(Maastricht University), Marcel Nijland(University Medical Center Groningen), Mels Hoogendoorn(Medisch Centrum Leeuwarden), Ward Posthuma(Leiden University Medical Center), Martin R. Schipperus(Rijnland Ziekenhuis), J. Martijn Kerst(The Netherlands Cancer Institute), Yvette van Norden(Erasmus MC Cancer Institute), Sabina Kersting(Haga Hospital), Erik W.A. Marijt(Radboud University Nijmegen), Shulamiet Wittebol(Valley Hospital), Julia Driessen(Amsterdam UMC Location University of Amsterdam), Reinier Raymakers(University Medical Center Utrecht), F. De Croon(Ikazia Ziekenhuis), M. Ronald Schaafsma(Medisch Spectrum Twente), Johan A. Dobber(Amsterdam University Medical Centers), Marinus H. J. van Oers(Academic Medical Center), Lina van der Straten(Erasmus MC)
Cited by 13
Related Papers
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630